Form 4 Tracker
Carl Dambkowski

Chief Medical Officer; Director · 5 filings · Latest: May 6, 2026

Apogee Therapeutics, Inc.
Oruka Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
APGE
Carl DambkowskiChief Medical OfficerMay 6, 2026
Sale
$84.145,500$462.8K207,023
APGE
Carl DambkowskiChief Medical OfficerMay 6, 2026
Option Exercise
$22.864,125$94.3K212,523
APGE
CARL DAMBKOWSKIMay 6, 2026
Proposed Sale
$83.2922,000$1.8M
APGE
Carl DambkowskiChief Medical OfficerApr 1, 2026
Sale
$84.845,500$466.6K208,398
APGE
Carl DambkowskiChief Medical OfficerApr 1, 2026
Option Exercise
$22.864,125$94.3K213,898
APGE
Carl DambkowskiChief Medical OfficerMar 4, 2026
Sale
$71.065,500$390.8K209,773
APGE
Carl DambkowskiChief Medical OfficerMar 4, 2026
Option Exercise
$22.864,125$94.3K215,273
APGE
Carl DambkowskiChief Medical OfficerFeb 4, 2026
Sale
$65.795,500$361.9K211,148
APGE
Carl DambkowskiChief Medical OfficerFeb 4, 2026
Option Exercise
$22.864,125$94.3K216,648
APGE
CARL DAMBKOWSKIJan 7, 2026
Proposed Sale
$78.2535,200$2.8M
APGE
CARL DAMBKOWSKIDec 4, 2025
Proposed Sale
$74.5510,900$812.6K
APGE
CARL DAMBKOWSKINov 5, 2025
Proposed Sale
$53.9010,785$581.3K
APGE
CARL DAMBKOWSKIJul 2, 2025
Proposed Sale
$44.2622,345$989.0K
APGE
CARL DAMBKOWSKIApr 2, 2025
Proposed Sale
$35.619,310$331.5K
APGE
CARL DAMBKOWSKIDec 11, 2024
Proposed Sale
$48.3818,160$878.6K
APGE
CARL DAMBKOWSKIOct 2, 2024
Proposed Sale
$57.3116,010$917.5K